Thursday, October 30, 2014 9:05:45 AM
UNIVEC, Inc. (OTCBB: UNVC) is focused on targeting its products for special diseases such as Sickle Cell Anemia, cancer, HIV/Aids, Hepatitis C. Multiple Sclerosis, Hemophilia and Drug Addiction. UNIVEC combines a targeted mix of production and sales to maintain a strong national market. UNIVEC has formed affiliate agreements with major pharmaceutical firms for production and distribution efficiency. Specialty Pharmaceuticals are high cost products that are not usually dispensed in retail pharmacies.
#PENNYSTOCKS
#OTCBB
#OTC
#UNVC
#UNIVEC
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM